8-K: Biora Therapeutics Shifts Focus to Licensing, Reports Q3 2024 Results and Secures Nasdaq Extension

Biora Therapeutics announced a strategic shift towards licensing its BioJet device, along with Q3 2024 financial results and an extension to regain Nasdaq compliance.

Summary

• Biora Therapeutics is focusing on licensing its 00-size BioJet device after rapid development progress.
• The company has increased the device's payload capacity while reducing its size, making it a leader in ingestible injectables.
• Biora is moving away from a co-development model to pursue multiple licensing agreements.
• The company is also working to advance its NaviCap platform for ulcerative colitis, potentially moving to a larger clinical trial.
• Biora has reduced operating expenses by approximately 40% to less than $2.5 million per month.
• The company received an extension until December 9 to regain compliance with Nasdaq listing requirements.
• Biora is actively seeking to increase its capitalization and exploring strategic alternatives.
• Third quarter 2024 operating expenses were $16.3 million, compared to $23.3 million in the same period of 2023.
• The net loss for the third quarter of 2024 was $18.4 million, compared to a net loss of $73.5 million for the same period in 2023.
• The company plans to share additional animal study data for the BioJet device in Q4 2024 and begin testing with collaborators' molecules in early 2025.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the BioJet technology and a strategic shift towards licensing, the company faces significant financial challenges, including a substantial net loss, a low cash position, and the risk of Nasdaq delisting. The need for a capital raise and the uncertainty around investor commitment also contribute to a negative sentiment.

Positives

• The 00-size BioJet device has increased payload capacity and reduced size, making it more attractive to pharmaceutical companies.
• The shift to a licensing model for the BioJet device could lead to multiple revenue streams.
• The company has significantly reduced operating expenses, improving its financial position.
• Biora received an extension to regain Nasdaq compliance, providing more time to address the issue.
• The Phase 1 trial data for BT-600 was well-received, potentially leading to a larger clinical trial.
• The company has made rapid progress in developing the smaller BioJet device.

Negatives

• The company is facing challenges in maintaining its Nasdaq listing and needs to increase its capitalization.
• There is no guarantee that investors will continue to provide funds to progress the company's programs.
• The company has incurred a net loss of $18.4 million in the third quarter of 2024.
• The company's cash position has decreased significantly from $15.2 million at the end of 2023 to $3.2 million at the end of Q3 2024.
• The company has significant liabilities including warrant liabilities of $18.7 million and derivative liabilities of $35 million.

Risks

• The company's ability to maintain its Nasdaq listing is uncertain, with a deadline of December 9.
• There is a risk that the company may not be able to raise sufficient capital to achieve its business objectives.
• The company's success depends on securing licensing agreements for its BioJet device.
• Clinical trial results may not be as expected, impacting the development of the NaviCap platform.
• The company faces risks related to regulatory approvals and commercialization of its products.
• The company has significant debt obligations including convertible notes that may need to be repurchased if delisted from the Nasdaq.

Future Outlook

Biora anticipates sharing data from additional canine studies with the double-zero size BioJet device during Q4 2024, performing studies of the double-zero Biora device with its own molecules in non-human primates during Q4 2024, and beginning testing of collaborators' molecules in primates in early 2025, with that round of testing completed during Q1 2025. The company also plans to announce an additional expanded collaboration agreement to test the double-zero BioJet device in primates during Q4 2024.

Management Comments

• We've made much faster progress than anticipated developing a smaller BioJet device that is highly desired by pharma companies, said Adi Mohanty, Chief Executive Officer of Biora Therapeutics.
• We expect to pursue licensing agreements within multiple verticals in the near term, which we believe is preferable to a single co-development partner for a period of time.
• We continue to believe, based on our extensive engagement with many pharma companies, that BioJet is the category-leading technology for oral delivery of macromolecules.
• We are working with our noteholders and investors to potentially increase the company's capitalization with the goal of maintaining our Nasdaq listing status after December 9.
• We are actively engaged with many parties regarding strategic alternatives and plan to provide a more detailed update soon.

Industry Context

The shift towards licensing the BioJet device aligns with the industry trend of pharmaceutical companies seeking innovative drug delivery technologies. The focus on oral delivery of macromolecules addresses a significant unmet need in the market, potentially disrupting traditional injection methods. The company's focus on a smaller device also reflects a broader trend towards patient-centric drug delivery solutions.

Comparison to Industry Standards

• Biora's BioJet device, with its 300+ microliter payload capacity, is positioned as a leader in the ingestible injectable category, surpassing competitors in terms of payload capacity.
• The company's focus on a 00-size capsule aligns with industry trends towards smaller, more patient-friendly devices, similar to other companies developing oral drug delivery systems.
• The reduction in operating expenses by 40% is a significant improvement compared to many biotech companies that often struggle with high burn rates.
• The company's move to a licensing model is a common strategy in the biotech industry, similar to companies like Alkermes and Ligand Pharmaceuticals, which focus on licensing their technologies to larger pharmaceutical companies.

Stakeholder Impact

• Shareholders face the risk of potential delisting from Nasdaq and dilution from a capital raise.
• Employees may be impacted by the company's cost-cutting measures and strategic shift.
• Potential partners and collaborators may be interested in the BioJet technology but will be cautious due to the company's financial situation.
• Creditors face the risk of non-payment if the company is unable to raise sufficient capital.

Next Steps

• Biora anticipates sharing data from additional canine studies with the double-zero size BioJet device during Q4 2024.
• Biora plans to perform studies of the double-zero Biora device with its own molecules in non-human primates during Q4 2024.
• The company anticipates announcing an additional expanded collaboration agreement to test the double-zero BioJet device in primates during Q4 2024.
• Testing of collaborators' molecules in primates is anticipated to begin in early 2025, with that round of testing completed during Q1 2025.
• The company is working to facilitate the proper regulatory interactions to determine the next steps for the NaviCap program.

Key Dates

Keywords

BioJet, NaviCap, oral delivery, licensing, Nasdaq compliance, clinical trials, biotech, pharmaceutical, capitalization, ulcerative colitis